Related Experiment Video
Updated: Feb 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients
Sarah Sim1, Jonas Bergh2,3, Mats Hellström2
1Department of Physiology & Pharmacology, Karolinska Institutet. SE171-76 Stockholm, Sweden.
Aim:
This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment.
Patients & Methods:
In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes.
Results:
Seven patients were characterized as poor metabolizer (PM), 22 patients as extensive metabolizer and 121 patients as intermediate metabolizer. The frequency of grade 3/grade 4 adverse events was higher in the PM group (p = 0.002). One PM subject who basically lacked enzyme activity died from typhlitis. Total 45 recurrences were reported after a median of 5-year follow-up; none of these was PM.
Conclusion:
The allelic variants CYP3A4*22 and CYP3A5*3 contribute to the interpatient variations of docetaxel.
Related Concept Videos
Treatment Resistant Cancers
Impact of Groups on Groups
Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
Impact of Groups on Individuals
Impact of Individuals on a Group
Impact of Schemas

